For laboratory use only. This product is intended for animal research only and not for use in humans.
Please enter valid quantity
Please log in to add favorites.
NULL OR EMPTY CART
BacteriSense™ 645 Targeted Fluorescent Pre-clinical Imaging Agent is a fast-clearing, targeted probe which binds to negatively charged lipids on the bacterial cell membrane, enabling the monitoring of infection progression in vivo non-invasively and in real time. Because the half-life of BacteriSense in vivo is as short as 45 minutes, image data can be acquired every day to track bacterial load during infection. This agent effectively targets infection caused by both gram-negative and gram-positive bacteria.
|Fluorescent Agent Type||Targeted|
|Optical Imaging Classification||Fluorescence Imaging|
|Product Brand Name||BacteriSense|
|Quantity in a Package Amount||1.0 Units|
|Shipping Condition||Blue Ice|
|Therapeutic Area||Bacterial infection|
|Unit Size||1 Vial (10 doses)|
|Wave Length||645 nm|
Infectious disease research requires the ability to study the progression of infection and effects of treatment in realistic time frames. BacteriSense Fluorescent Pre-clinical Imaging Agent is a fast-clearing, targeted probe which binds to negatively charged lipids on the bacterial cell membrane, enabling the monitoring of infection progression in vivo non-invasively and in real time. Because the half-life of BacteriSense in vivo is as short as 45,minutes, image data can be acquired every day to track bacterial load during infection.
Researchers trust our in vivo imaging solutions to give them reliable, calibrated data that reveals pathway characterization and therapeutic efficacies for a broad range of indications. Our reagents, instruments, and applications support have helped hundreds of research projects over the years. And our hard-earned expertise makes us a trusted provider of pre-clinical imaging solutions— with more than 9,000 peer reviewed articles as proof.
Bacterial infection is a serious and costly clinical issue, so there is significant need for preclinical tools for assessing infection and therapeutic intervention. Rapid and non-invasive imaging technologies and targeted imaging agents would prove invaluable in diagnosing and managing bacterial infections. To this end, we developed a unique type of fluorescent agent that can quickly target bacteria, providing a fluorescent method to quantify bacterial load during infection as early as one hour post-injection. A red cationic agent (BacteriSenseTM 645) targeting the negative charge at the surface of bacteria was developed
BacteriSense™ 645 is a near-infrared labeled fluorescent in vivo imaging agent that targets Gram positive and Gram negative bacteria.
The primary goal of preclinical imaging is to improve the odds of clinical success and reduce drug discovery and development time and costs. Advances in non-invasive in vivo imaging techniques have raised the use of animal models in drug discovery and development to a new level by enabling quick and efficient drug screening and evaluation. Read this White Paper to learn how preclinical in vivo imaging helps to ensure that smart choices are made by providing Go/No-Go decisions and de-risking drug candidates early on, significantly reducing time to the clinic and lowering costs all while maximizing biological understanding.